Disease · HP_0010819

Atonic seizure

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. Atonic seizure. Diseases, record HP_0010819. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0010819

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: Atonic seizure
Open Targets ID: HP_0010819
Other names: Astatic seizure, Astatic seizures, Atonic seizures, Drop attacks, Drop seizures, Hypotonic seizure
Highest stage of its drugs: Phase 3, for 2 of its 2 drugs, from ClinicalTrials.gov

Source Open Targets

Drugs2

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CLOBAZAM	CHEMBL70418	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
CANNABIDIOL	CHEMBL190461	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets

Targets17

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
CNR1	Cannabinoid receptor 1	1	Cannabinoid CB1 receptor negative allosteric modulator	Phase 3	https://conductscience.org/library/genes/1268	Drugs and targets
GABRA1	GABA-A receptor; anion channel	1	GABA-A receptor; anion channel positive allosteric modulator	Phase 3	https://conductscience.org/library/genes/2554	Drugs and targets
GABRA2	GABA-A receptor; anion channel	1	GABA-A receptor; anion channel positive allosteric modulator	Phase 3	https://conductscience.org/library/genes/2555	Drugs and targets
GABRA3	GABA-A receptor; anion channel	1	GABA-A receptor; anion channel positive allosteric modulator	Phase 3	https://conductscience.org/library/genes/2556	Drugs and targets
GABRA4	GABA-A receptor; anion channel	1	GABA-A receptor; anion channel positive allosteric modulator	Phase 3	https://conductscience.org/library/genes/2557	Drugs and targets
GABRA5	GABA-A receptor; anion channel	1	GABA-A receptor; anion channel positive allosteric modulator	Phase 3	https://conductscience.org/library/genes/2558	Drugs and targets
GABRA6	GABA-A receptor; anion channel	1	GABA-A receptor; anion channel positive allosteric modulator	Phase 3	https://conductscience.org/library/genes/2559	Drugs and targets
GABRB1	GABA-A receptor; anion channel	1	GABA-A receptor; anion channel positive allosteric modulator	Phase 3	https://conductscience.org/library/genes/2560	Drugs and targets
GABRB2	GABA-A receptor; anion channel	1	GABA-A receptor; anion channel positive allosteric modulator	Phase 3	https://conductscience.org/library/genes/2561	Drugs and targets
GABRB3	GABA-A receptor; anion channel	1	GABA-A receptor; anion channel positive allosteric modulator	Phase 3	https://conductscience.org/library/genes/2562	Drugs and targets

1 to 10 of 17

See all 17 targets

Trials5

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01160770	Safety and Effectiveness of Open-Label Clobazam in Subjects With Lennox-Gastaut Syndrome	Phase 3	267	2013-05-06	Lennox-Gastaut Syndrome	CLOBAZAM	Its record names the disease	ClinicalTrials.gov
NCT00518713	Clobazam in Patients With Lennox-Gastaut Syndrome	Phase 3	238	2012-02-09	Epilepsy, Epilepsy, Generalized, Seizures	CLOBAZAM	Its record names the disease	ClinicalTrials.gov
NCT02224560	Efficacy and Safety of GWP42003-P for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults	Phase 3	225	2018-07-27	Epilepsy, Lennox Gastaut Syndrome	CANNABIDIOL	Its record names the disease	ClinicalTrials.gov
NCT02224690	A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults	Phase 3	171	2018-07-27	Epilepsy, Lennox-Gastaut Syndrome	CANNABIDIOL	Its record names the disease	ClinicalTrials.gov
NCT00162981	Clobazam in Subjects With Lennox-Gastaut Syndrome	Phase 2	68	2012-02-09	Epilepsy, Epilepsy, Generalized, Seizures	CLOBAZAM	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials3

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
GWP42003-P 20 mg/kg/Day Dose vs Placebo: Number Of Participants With a ≥50% Reduction From Baseline in Drop Seizure Frequency During The Treatment Period	38 of 86	20 of 85	171	NCT02224690	Trial comparisons
GWP42003-P 20 mg/kg/Day Dose vs Placebo: serious adverse events	20 of 86	4 of 85	171	NCT02224690	Trial comparisons
Clobazam Low Dose vs Clobazam High Dose: serious adverse events	1 of 32	3 of 36	68	NCT00162981	Trial comparisons

Papers from its trials9

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
29768152	RESULT	1	PubMed
23141144	RESULT	1	PubMed
21956725	RESULT	1	PubMed
40775196	DERIVED	2	PubMed
37052803	DERIVED	2	PubMed
33825230	DERIVED	3	PubMed
33797076	DERIVED	2	PubMed
30955420	DERIVED	1	PubMed
27683846	DERIVED	2	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/HP_0010819

GET https://conductscience.org/api/diseases/v1/HP_0010819/drugs

API reference For AI assistants